Research ArticleAccepted Article
Open Access
Frequency of symptomatic adverse events in rheumatoid arthritis: an exploratory online survey
Glen S. Hazlewood, Orit Schieir, Vivian Bykerk, Kamso Mujaab, Peter Tugwell, George Wells, Dawn Richards, Laurie Proulx, Pauline M. Hull and Susan J. Bartlett
The Journal of Rheumatology March 2022, jrheum.210688; DOI: https://doi.org/10.3899/jrheum.210688
Glen S. Hazlewood
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
Orit Schieir
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
Vivian Bykerk
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
Kamso Mujaab
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
Peter Tugwell
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
George Wells
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
Dawn Richards
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
Laurie Proulx
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
Pauline M. Hull
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
Susan J. Bartlett
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Richmond, BC, Canada; Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada; Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA; Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada ; Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada. Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267]. Conflicts of interest: V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board); L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies. Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event); SJ Bartlett: Honoria: Organon, Janssen, Pfizer. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew{at}ucalgary.ca
Abstract
Objective To generate initial data on the frequency and impact of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patients' perspective.
Methods We conducted an exploratory online survey asking patients with RA to indicate whether they currently or had ever experienced the 80 different symptomatic AEs included in the Patient-Reported Outcomes version of The Common Terminology Criteria For Adverse Events (PRO-CTCAE™). Results were summarized to report their frequency and regression models were used to estimate their associations with RA medication use and overall bother.
Results The 560 patients who completed the survey and reported taking at least one RA medication (DMARD, steroids, NSAIDs), had a mean disease duration of 8 years, and were on a wide range of DMARDs. The number of symptomatic AEs experienced in the past 7 days was none (6%), 1-10 (28%), 11-20 (28%), and >20 (38%). Overall, most participants reported that side effects bothered them somewhat (28%), quite a bit (24%) or very much (15%). In multivariable regression analyses, current prednisone and NSAID use were associated with the greatest number of current side effects (26 and 22 respectively). Many of the strongest associations between current symptomatic AEs and medication use aligned with known side effect profiles.
Conclusion In this exploratory online survey, patients with RA reported frequent symptomatic AEs with their medications that are bothersome. Further work is needed to develop and validate a measure for use in patients with rheumatic disease.
In this issue
The Journal of Rheumatology
Vol. 53, Issue 8
1 Aug 2026
Accepted manuscript
Frequency of symptomatic adverse events in rheumatoid arthritis: an exploratory online survey
Glen S. Hazlewood, Orit Schieir, Vivian Bykerk, Kamso Mujaab, Peter Tugwell, George Wells, Dawn Richards, Laurie Proulx, Pauline M. Hull, Susan J. Bartlett
The Journal of Rheumatology Mar 2022, jrheum.210688; DOI: 10.3899/jrheum.210688
Accepted manuscript
Frequency of symptomatic adverse events in rheumatoid arthritis: an exploratory online survey
Glen S. Hazlewood, Orit Schieir, Vivian Bykerk, Kamso Mujaab, Peter Tugwell, George Wells, Dawn Richards, Laurie Proulx, Pauline M. Hull, Susan J. Bartlett
The Journal of Rheumatology Mar 2022, jrheum.210688; DOI: 10.3899/jrheum.210688
